Pretreatment SUV of the metastatic neck lymph nodes predicts neck control and survival in patients with stage IV oro/hypopharyngeal cancers | ||||
Egyptian Journal Nuclear Medicine | ||||
Article 4, Volume 4, Issue 4, December 2011, Page 27-36 PDF (384.05 K) | ||||
Document Type: Original Paper, Oncology | ||||
DOI: 10.21608/egyjnm.2011.5488 | ||||
View on SCiNiTO | ||||
Authors | ||||
Yasser Gaber Abdelhafez 1; Hosna Moustafa2 | ||||
1Nuclear Medicine Unit, South Egypt Cancer Institute, Assuit University. | ||||
2Oncology and Nuclear Medicine Department, Kasr Al-Aini Hospital, Cairo University, Egypt. | ||||
Abstract | ||||
Purpose To investigate the prognostic significance of standardized uptake value (SUV) of metastatic neck lymph nodes measured on FDG PET/CT in patients with stage IV oro/hypopharyngeal cancers treated by definitive chemoradiotherapy (CCRT). Methods Retrospective analysis of 65 patients with clinically N+ stage IV SCC of the oro/hypopharyngeal squamous cell carcinoma (SCC) who underwent FDG PET/CT scans for primary staging. Follow-up continued till death or at least 24 months from the start of treatment. The primary study endpoint was neck control (NC). The log-rank test and Cox proportional hazard analysis were used to identify significant prognostic factors. Results The 3-year NC rate was 53%. In univariate analysis, N3 status and nodal SUV ≥ 9.8 were significantly associated with reduced NC. In multivariable analyses, nodal SUV retained its independent prognostic significance as a predictor of NC. Lymph node stage was an independent predictor of disease specific survival (DSS). A prognostic scoring system was constructed as follows: score 0 = N0-N2 and nodal SUV < 9.8; score 1 = N3 or nodal SUV ≥ 9.8; and score 2 = N3 and nodal SUV ≥ 9.8. Patients with a score of 2 showed the worst NC (hazard ratio [HR], 95% confidence interval [CI] = 10.5, 3.3-33.1; P < 0.001) and the lowest DSS (HR, 95% CI = 6.4, 2.2-18.7; P = 0.001). Conclusion The combination of high nodal SUV and N3 neck disease identifies a subgroup of high-risk stage IV oro/hypopharyngeal SCC patients. Further prospective studies are warranted to validate this finding. | ||||
Keywords | ||||
Neck lymph nodes ٠ FDG PET SUV ٠; Hypopharynx ٠ Oropharynx ٠ Prognosis ٠; Concomitant chemoradiotherapy | ||||
Statistics Article View: 197 PDF Download: 252 |
||||